Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

[1]  J. Verweij,et al.  Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer , 2001, British Journal of Cancer.

[2]  J. Verweij,et al.  Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Verweij,et al.  Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Verweij,et al.  Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  W. Mcguire.  High-dose chemotherapeutic approaches to ovarian cancer management. , 2000, Seminars in oncology.

[6]  J Verweij,et al.  Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients , 2000, Anti-cancer drugs.

[7]  J. Verweij,et al.  Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Hamada,et al.  Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[10]  J. Schellens,et al.  In vitro antagonistic cytotoxic interactions between platinum drugs and taxanes on bone marrow progenitor cell CFU-GM. , 1999, Anti-cancer drugs.

[11]  D M Woodcock,et al.  Phase I trial of cremophor EL with bolus doxorubicin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Verweij,et al.  Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. , 1998, Analytical biochemistry.

[13]  J. Verweij,et al.  Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  J. Verweij,et al.  Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Verweij,et al.  Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. J. van den Bent,et al.  A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer , 1997, Cancer Chemotherapy and Pharmacology.

[17]  J. Verweij,et al.  Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Beijnen,et al.  Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. , 1996, Cancer research.

[19]  J. Verweij,et al.  Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. , 1996, Journal of chromatography. B, Biomedical applications.

[20]  J. Verweij,et al.  Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  B. Henderson,et al.  BIODISTRIBUTION AND PDT EFFICACY OF A KETOCHLORIN PHOTOSENSITIZER AS A FUNCTION OF THE DELIVERY VEHICLE , 1994, Photochemistry and photobiology.

[22]  J. Verweij,et al.  Weekly high-dose cisplatin in malignant pleural mesothelioma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Verweij,et al.  Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. , 1993, British Journal of Cancer.

[24]  D. Kessel.  PROPERTIES OF CREMOPHOR EL MICELLES PROBED BY FLUORESCENCE , 1992, Photochemistry and photobiology.

[25]  V. Nink,et al.  Reversal of multidrug resistance by surfactants. , 1992, British Journal of Cancer.

[26]  E. Schneider,et al.  GM‐CSF in association with IL‐1 triggers day‐8 CFU‐S into cell cycle: Role of histamine , 1991, Journal of cellular physiology.

[27]  E K Rowinsky,et al.  Sequences of taxol and cisplatin: a phase I and pharmacologic study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Schneider,et al.  New role for histamine in interleukin‐3‐induced proliferation of hematopoietic stem cells , 1990, Journal of cellular physiology.

[29]  P. Drings.  European experience with ifosfamide in non-small cell lung cancer. , 1989, Seminars in oncology.

[30]  R. Evans,et al.  Modification of the bone marrow toxicity of cis-diamminedichloroplatinum(II) in mice by diethyldithiocarbamate. , 1984, Cancer research.

[31]  A. Eschalier,et al.  Study of histamine release induced by acute administration of antitumor agents in dogs , 2004, Cancer Chemotherapy and Pharmacology.

[32]  A. Adjei,et al.  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Verweij,et al.  Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck. , 1997, European journal of cancer.

[34]  A. G. Ellis,et al.  Inhibition of etoposide elimination in the isolated perfused rat liver by Cremophor EL and Tween 80 , 1996, Cancer Chemotherapy and Pharmacology.

[35]  B. Williams,et al.  Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil. , 1995, International journal of radiation biology.

[36]  K. Tasaka,et al.  The influence of histamine on precursors of granulocytic leukocytes in murine bone marrow. , 1988, Life sciences.

[37]  Y. Shounan,et al.  The influence of histamine at various concentrations on the cell cycle state of hematopoietic stem cells (CFU-s). , 1988 .

[38]  M. Hacker,et al.  Cremophor and Emulphor induced alterations of serum lipids and lipoprotein electrophoretic patterns of dogs. , 1981, Research communications in chemical pathology and pharmacology.